Epigenic Therapeutics secured $60 million in Series B funding to accelerate clinical trials of its pioneering CRISPR-based epigenetic therapies targeting chronic hepatitis B. This approach leverages gene editing technologies aimed at reshaping epigenetic regulation rather than DNA sequence alteration, potentially offering a novel therapeutic avenue. The sizable investment underscores growing confidence in epigenetic modulation as a frontier in precision medicine for chronic infectious diseases.